The JOM.TEST Program in Malaysia offers fast, comforting, and confidential self-testing and self-sampling for vulnerable populations. It aims to combat stigma and discrimination and improve access to HIV, STIs, and hepatitis services.

2 views • 12 slides

Clinical guidelines provide evidence-based recommendations for treating and curing chronic HCV infection in adults to improve treatment rates, reduce morbidity and mortality, and support the New York State Hepatitis C Elimination Plan. Recommendations include considerations in HCV treatment initiati

0 views • 28 slides

Hepatitis C, a viral infection affecting the liver, has notable implications in Ireland, with key transmission routes, clinical manifestations, and long-term consequences shaping its epidemiology. From transmission patterns to chronic infection risks, understanding the natural history and prevalence

0 views • 24 slides

LiveRx Study aims to evaluate the impact of a collaborative program involving community pharmacies and organizations in treating HCV in Alberta. By leveraging pharmacist-led interventions, the initiative focuses on increasing HCV screening, diagnosis, and linkage to care, ultimately aiming to eradic

2 views • 13 slides

This presentation outlines the initiative to address the syndemic at Cass Lake IHS, focusing on Hepatitis C and harm reduction services. It discusses the background of Hepatitis C, the challenges faced in previous treatments, and the new pharmacist-run HCV clinic model. The aim is to educate on the

1 views • 35 slides

Explore the distinction between reactive arthritis and viral arthritis in the context of COVID-19, discussing symptoms, triggers, and potential long-term consequences on joint health. Learn how viral infections can lead to acute arthralgia and arthritis, including common pathogens such as Hepatitis

0 views • 30 slides

Vaccines Market Size, Share, Forecast, & Trends Analysis by Indication (Pneumococcal, Influenza, HPV, DTP, MMR, Hepatitis, COVID-19) Administration (IM, SC, Oral) Type (Inactivated, Combination) Valence (Multivalent, Monovalent) - Global Forecast to 2031\n

1 views • 5 slides

Diagnostic Specialty Antibodies Market by Type (Primary, Secondary), Clonality (Monoclonal, Polyclonal), Technique (WB, Rapid Test, IHC, IP), Conjugate, and Application (Dengue, Malaria, Hepatitis, HIV, E. coli , Tuberculosis, Pneumonia, Cancer)- For

0 views • 6 slides

Ethiopia's initial experience on Hepatitis B birth dose (HepB-BD) pilot implementation includes background statistics, HBsAg prevalence, hepatitis B vaccination coverage, distribution of HBV infection, existing guidelines/strategies, and activities prior to the start of HepB-BD piloting.

0 views • 17 slides

Demonstrating competency in infection control, abdominal assessment, specimen collection, and communication is crucial in nursing care for patients with Hepatitis C. The SCENS program focuses on key learning objectives to enhance clinical proficiency, address potential issues, and understand the com

0 views • 12 slides

Hepatitis B vaccination coverage in Botswana faces challenges like poor documentation and premature infants not receiving the birth dose. Opportunities for improvement include enhancing data collection, evaluating the immunization program, and strengthening perinatal committees for quality care.

0 views • 9 slides

Explore the difference between genuine and counterfeit Hepatitis B vaccines in Uganda, as detailed by the National Drug Authority. Learn about the authorized vaccine on the market, counterfeit batch numbers, fake addresses on invoices/receipts, and the availability of vaccines in private sectors. St

0 views • 8 slides

Bloodborne pathogens (BBPs) are pathogenic microorganisms found in human blood that can cause diseases like HIV, Hepatitis B, and Hepatitis C. Public safety officers and sergeants face occupational exposure to BBPs and should follow OSHA's BBP Standard to protect themselves. Training, vaccinations,

0 views • 41 slides

Covering the basics of OSHA Bloodborne Pathogens Standard, this training material provides essential information on bloodborne pathogens, including Hepatitis B Virus (HBV). It emphasizes the importance of training for individuals with occupational exposure, outlining crucial topics such as Hepatitis

2 views • 56 slides

Canine Infectious Hepatitis (ICH), also known as Rubarth's Disease, is caused by Canine Adenovirus-1 (CAdV-1), affecting dogs of all ages. The virus primarily targets hepatocytes, leading to acute hepatitis, as well as respiratory and ocular issues. Transmission occurs through contact with infected

6 views • 7 slides

In Ghana, the introduction plan for Hepatitis B BD involves evaluating disease burden, estimating seroprevalence among pregnant women, obtaining necessary approvals, presenting evidence to NITAG, and seeking support for introduction. A policy for screening and prevention is in place, aiming to addre

1 views • 10 slides

Mozambique is gearing up to introduce the Hepatitis B birth dose as a strategic approach in its immunization program, aiming to tackle the high prevalence of HBV within the population, particularly among women and HIV-positive individuals. The country's existing policies on screening pregnant women

0 views • 15 slides

Required immunization documentation, including Hepatitis B, MMR, Tetanus, Varicella, and Influenza, must be submitted before enrolling in Nursing classes. A titer is a blood test measuring immunity to diseases. Details on Hepatitis B vaccination series, MMR requirements, and non-responder status are

0 views • 13 slides

Core trainers in CPG management of Chronic Hepatitis C in adults must focus on pre-treatment assessment to identify co-morbidities, assess liver status, determine fibrosis severity, and conduct necessary blood investigations. Utilizing non-invasive methods for liver fibrosis assessment is crucial fo

0 views • 13 slides

The National Viral Hepatitis Control Program in India is working towards combating viral hepatitis and achieving SDG goal 3.3 through a comprehensive approach that includes awareness generation, prevention, management, and financing under the NHM. The aim is to eliminate hepatitis C by 2030, reduce

0 views • 19 slides

Explore the latest advancements in the treatment of Hepatitis C virus (HCV) in HIV-infected individuals through a detailed presentation by Dr. Kara W. Chew. Learn about the initial evaluation for HCV, treatment options for different genotypes, management of advanced fibrosis, recommended approaches

0 views • 9 slides

Discussing the goals, treatment options, and global impact of Hepatitis C in individuals with HIV infection, this presentation by Dr. David L. Thomas from Johns Hopkins Medical Institutions sheds light on important aspects such as mortality projections, WHO elimination goals, and targets for hepatit

0 views • 40 slides

The 2022 report on Hepatitis C in England shows a continued decline in the prevalence of chronic HCV infection, with around 81,000 individuals estimated to be affected in 2020. The report also highlights the distribution of infections among individuals with different drug injecting histories. Data f

0 views • 41 slides

The Canadian Task Force on Preventive Health Care (CTFPHC) released recommendations on Hepatitis C screening for adults in 2017. The guidelines provide an overview of screening methods, key findings, implementation considerations, and conclusions. Those at higher risk for HCV in Canada include indiv

0 views • 38 slides

Zoonotic hepatitis A virus infections primarily affect humans and nonhuman primates, with transmission occurring through fecal-oral route. This article delves into the reservoir, mode of transmission, clinical signs, and diagnosis of hepatitis A, shedding light on its impact on both species. Nonhuma

0 views • 22 slides

The Department of Health in Florida has released the 2019 data on the epidemiology of Hepatitis B and C as of January 21, 2021. The report includes information on acute and chronic cases, technical notes on case definitions, and changes in national case definitions in 2020. Acute cases require speci

0 views • 35 slides

Viral hepatitis is caused by various hepatotropic viruses, including Hepatitis A, B, C, D, and E. This type of liver inflammation can manifest acutely or chronically, leading to symptoms such as jaundice, abdominal pain, nausea, and fatigue. Hepatitis A virus, in particular, is primarily transmitted

0 views • 36 slides

Hepatitis B infection is a viral liver disease transmitted through various means such as contact with infected body fluids. The virus can lead to acute or chronic infection, potentially causing severe liver complications. Vaccination programs and lifelong treatment options aim to manage and prevent

0 views • 30 slides

Dr. Fred Stephen Sarfo's research on Hepatitis C in Ghana reveals a notable sero-prevalence of the virus across various populations such as blood donors, prisons inmates, and more. The studies show varying HCV antibody frequencies, highlighting the need for continued surveillance and targeted interv

0 views • 25 slides

The CDC National Notifiable Diseases Surveillance System data reveals hepatitis C trends, reported cases per 100,000 population across age groups, gender, and ethnicity. Risk factors such as injection drug use, sexual contact, multiple sex partners, and occupation exposures are identified and discus

0 views • 7 slides

Acute liver failure is a severe condition characterized by rapid liver dysfunction within 6 months of symptom onset, leading to encephalopathy, coagulopathy, and jaundice. This condition can be classified as hyperacute, acute, subacute, fulminant, or sub-fulminant based on the duration from jaundice

0 views • 16 slides

This study, supervised by Dr. Christina Greenaway, aims to estimate and compare healthcare utilization in Quebec immigrants and non-immigrants diagnosed with chronic Hepatitis C infection. The research seeks to identify predictors of all-cause and liver-related healthcare utilization. With rising he

0 views • 25 slides

Liver disease in Canada, particularly hepatitis B, is a concerning issue highlighted in the report prepared by the Canadian Liver Foundation in March 2013. The incidence of acute hepatitis B is declining, especially among vaccinated age groups. The prevalence of chronic hepatitis B in Canadian immig

0 views • 58 slides

This guidance provides detailed information on COVID-19 and liver disease, covering topics such as COVID-19 overview, liver test abnormalities, co-morbidities, viral hepatitis B and C, metabolic dysfunction, autoimmune hepatitis, clinical care aspects, complications management, screening for HCC, an

0 views • 14 slides

The surveillance and notification of Hepatitis E cases in Ireland have been detailed, including the introduction of universal blood donor screening, notifiable disease status, and enhanced surveillance measures. The data shows trends in notifications, blood donor screening results, clinical cases, a

0 views • 13 slides

Investigation into hepatitis A transmission involving two nurses in Fort Bend County and Harris County, Texas, who worked for a pediatric home healthcare agency. Contact tracing efforts reveal exposures among patients, household contacts, and other nurses, leading to monitoring for symptoms and admi

0 views • 26 slides

The Health Protection Surveillance Centre presents the annual trends update on HIV, Hepatitis, and STIs among Men Who Have Sex with Men (MSM) in Ireland up to the end of 2018. The report explores the overall trends in HIV diagnoses and rates, probable routes of transmission, previous diagnosis histo

0 views • 35 slides

Learn about the Hepatitis C elimination program at Lummi Tribal Health Center, focusing on defining elimination, required interventions for HCV elimination, and the Lummi program's description. The activity offers 7 contact hours upon completion. No conflicts of interest are present, and the event i

0 views • 24 slides

The data presented focuses on the impact of the COVID-19 response on hepatitis elimination efforts in the Americas region. It includes information on changes in in-person clinic visits, declines in hepatitis B and C screening and treatment, and disruptions in opioid substitution therapy. The graphs

0 views • 13 slides

This presentation by Dr. Ricardo A. Franco focuses on the challenges faced in managing and treating patients with HIV/Hepatitis C virus coinfection. It discusses the burden of HCV mono-infection and HIV/HCV co-infection, the impact of HIV co-infection on survival in HCV-related cirrhosis, and the ro

0 views • 26 slides